BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanthala SP, Liu YY, Singh S, Sable R, Pallerla S, Jois SD. A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization. Oncotarget 2017;8:74244-62. [PMID: 29088782 DOI: 10.18632/oncotarget.19013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Gauthier T, Liu D. Peptide Synthesis: Methods and Protocols. Peptide Therapeutics 2022. [DOI: 10.1007/978-3-031-04544-8_2] [Reference Citation Analysis]
2 Singh SS, Mattheolabakis G, Gu X, Withers S, Dahal A, Jois S. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models. Eur J Med Chem 2021;216:113312. [PMID: 33667849 DOI: 10.1016/j.ejmech.2021.113312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Kaufman NEM, Dhingra S, Jois SD, Vicente MDGH. Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR). Molecules 2021;26:1076. [PMID: 33670650 DOI: 10.3390/molecules26041076] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
4 Singh SS, Dahal A, Shrestha L, Jois SD. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. Curr Med Chem 2020;27:5274-316. [PMID: 30854949 DOI: 10.2174/0929867326666190222183219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
5 Shrestha L, Singh SS, Parajuli P, Dahal A, Mattheolabakis G, Meyer S, Bhattacharjee J, Jois SD. In vivo studies of a peptidomimetic that targets EGFR dimerization in NSCLC. J Cancer 2020;11:5982-99. [PMID: 32922539 DOI: 10.7150/jca.46320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sable R, Jambunathan N, Singh S, Pallerla S, Kousoulas KG, Jois S. Proximity ligation assay to study protein-protein interactions of proteins on two different cells. Biotechniques 2018;65:149-57. [PMID: 30227746 DOI: 10.2144/btn-2018-0049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
7 Dong Q, Yu P, Ye L, Zhang J, Wang H, Zou F, Tian J, Kurihara H. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations. Sci Rep 2019;9:5692. [PMID: 30952931 DOI: 10.1038/s41598-019-42245-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
8 Pallerla S, Naik H, Singh S, Gauthier T, Sable R, Jois SD. Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3. J Pept Sci 2018;24. [PMID: 29436155 DOI: 10.1002/psc.3066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ran X, Gestwicki JE. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area. Curr Opin Chem Biol 2018;44:75-86. [PMID: 29908451 DOI: 10.1016/j.cbpa.2018.06.004] [Cited by in Crossref: 126] [Cited by in F6Publishing: 134] [Article Influence: 31.5] [Reference Citation Analysis]